Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – Should You Buy?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) gapped up before the market opened on Wednesday. The stock had previously closed at $42.80, but opened at $46.00. Swedish Orphan Biovitrum shares last traded at $46.00, with a volume of 102 shares traded.

Analysts Set New Price Targets

BIOVF has been the subject of several recent analyst reports. Pareto Securities downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Nordea Equity Research lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. The company’s fifty day moving average is $46.36 and its 200-day moving average is $46.46. The stock has a market cap of $16.38 billion, a PE ratio of 21.80 and a beta of 0.47.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.

Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.